**Supplementary File 2**

**Safety and Efficacy of ETC-1002 in hypercholesterolemic patients: a protocol for a meta-analysis of randomized controlled trials**

* **Objective:** To summarize evidence on the tolerability and efficacy of ETC-1002 in hypercholesterolemic patients through systematic review of published randomized controlled trials (RCTs).
* **Population:** Hypercholesterolemic men and women aged 18 to 80 years old**.**
* **Intervention:** ETC-1002 with all doses
* **Control:** any other agent with head-to-head comparison
* **Outcomes:** Efficacy **(**LDL-C, HDL-C, non-HDL-C, and total cholesterol) and safety outcomes (adverse events, serious adverse events, adverse events leading to discontinuation, headache, and myalgia)
* **Study design:** A meta-analysis of randomized controlled trials
* **Proposed search strategy (Edited):** (Bempedoic acid OR ETC-1002 OR ESP55016) AND ([Familial hypercholesterolemia](https://www.ncbi.nlm.nih.gov/pubmed/28884604) OR [Hypercholesterolemic](https://www.ncbi.nlm.nih.gov/pubmed/27206943) OR Hypercholesteremia OR High Cholesterol Levels OR Elevated Cholesterol OR [Hyperlipidemia](https://www.ncbi.nlm.nih.gov/pubmed/28064554) OR Dyslipidemia). The following databases will be searched: Scopus, Cochrane Central, PubMed, Embase, and Web of Science.
* **Data extraction methods:** The following data are planned for extraction: 1) Study and patient characteristics for display in baseline characters table, 2) risk of bias domains, and 3) Outcomes: for data analysis.
* **Data analysis:** All extracted data will be analyzed using the RevMan software (version 5.3), either in the form of mean difference (for continuous data) or odds ratio (for dichotomous data) with 95% confidence interval. Heterogeneity and publication bias will be dealt with as per the recommendations of the Cochrane handbook for systematic reviews of interventions. Trials not fitting for data analysis will be discussed in a narrative approach.
* **Risk of bias assessment:** The Cochrane risk of bias assessment tool will be used to assess the risk of bias within the included trials.